PRKDC and cancer: Furthermore, the compound SU11752 was found to inhibit DNA-PKcs through competition with ATP and has an IC50 of 0.13 μM; at 12 μM concentrations it inhibits DSB repair, and at concentrations exceeding 50 μM, it displays a 5-fold radiosensitization of cancer cells in vitro [234].